Neurocrine(US:NBIX) Prnewswire·2025-10-28 20:01Core Insights - Neurocrine Biosciences reported strong financial results for Q3 2025, with INGREZZA achieving net product sales of $687 million, reflecting a 12% year-over-year growth, while CRENESSITY generated $98 million in net product sales [1][6][13] - The company highlighted the positive impact of its products on patients and emphasized its commitment to advancing innovative therapies in neuroscience [2][4] Financial Performance - Total revenues for Q3 2025 were $794.9 million, up from $622.1 million in Q3 2024, marking a 28% year-over-year increase [4][16] - GAAP net income for Q3 2025 was $209.5 million, compared to $129.8 million in Q3 2024, with diluted earnings per share increasing from $1.24 to $2.04 [13][16] - Non-GAAP net income for Q3 2025 was $222.1 million, up from $189.2 million in Q3 2024, with diluted earnings per share rising from $1.81 to $2.17 [13][19] Product Sales Highlights - INGREZZA's net product sales for Q3 2025 were $687 million, showing a 10% sequential growth over Q2 2025 and a 12% year-over-year growth [6][8] - CRENESSITY's net product sales reached $98 million, with 540 new patient enrollment start forms, indicating strong demand and 80% reimbursement coverage for dispensed scripts [6][8] Research and Development - The company initiated a second Phase 3 registrational clinical trial for direclidine, targeting adults with schizophrenia, and presented promising data from the Phase 2 SAVITRI study for osavampator in major depressive disorder [5][6] - R&D expenses for Q3 2025 were $250 million, up from $195 million in Q3 2024, reflecting increased investment in clinical programs [4][16] Corporate Developments - Neurocrine announced the appointment of Mike Sibley as Senior Vice President and General Manager of the Neuropsychiatry franchise, aiming to enhance the sales and marketing strategy for its neuropsychiatry products [5][6] - The company plans to expand its INGREZZA and CRENESSITY sales teams to maximize commercial momentum, with completion expected by the end of Q1 2026 [5][6]